1. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion
- Author
-
Ji-Youn Han, Maurizio Ceppi, Geon Kook Lee, Ian James, Jin Young Kim, Martin Weisser, Hye Sook Kim, Wolfgang Jacob, Dong Hoon Shin, and Kun Young Lim
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Adult ,Cancer Research ,Lung Neoplasms ,Oncogene Proteins, Fusion ,Receptor, ErbB-3 ,Neuregulin-1 ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Erlotinib Hydrochloride ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,mental disorders ,medicine ,Adenocarcinoma of the lung ,Humans ,Molecular Targeted Therapy ,skin and connective tissue diseases ,Neoplasm Staging ,Clinical Trials as Topic ,Lung ,biology ,business.industry ,Lumretuzumab ,Middle Aged ,medicine.disease ,Adenocarcinoma, Mucinous ,Progression-Free Survival ,Blockade ,body regions ,ErbB Receptors ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Monoclonal ,Cancer research ,biology.protein ,Adenocarcinoma ,Female ,Erlotinib ,Antibody ,business ,Proto-Oncogene Proteins c-akt ,medicine.drug ,Signal Transduction - Abstract
Rearrangements of NRG1 have been identified in invasive mucinous adenocarcinoma of the lung (IMA), formerly referred to as mucinous bronchioloalveolar carcinoma. NRG1 ligand signals through induction of HER2-HER3 heterodimers, thus leading to PI3K-AKT pathway activation. Therefore, targeting HER2, HER3 and the downstream pathway may be a hypothesis-driven strategy for IMA with NRG1 fusion. Herein we reported two patients who benefited from lumretuzumab, a monoclonal anti-HER3 antibody, in combination of erlotinib during a clinical trial (NCT01482377). At least sixteen weeks of progression-free survival were achieved without any unacceptable toxicity.
- Published
- 2018